Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The Prescribing Practice for COPD: Relationship to Circadian Rhythm, Disease Severity, and Clinical Phenotype in the STORICO Observational Study.

Tytuł:
The Prescribing Practice for COPD: Relationship to Circadian Rhythm, Disease Severity, and Clinical Phenotype in the STORICO Observational Study.
Autorzy:
Incalzi RA; University Biomedical Campus of Rome, Via Alvaro del Portillo, 21, 00128, Rome, Italy. .
Blasi F; Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Via Francesco Sforza, 35, 20122, Milan, Italy.
Canonica GW; Personalized Medicine Asthma and Allergy Clinic, Humanitas University Humanitas Research Hospital Rozzano (Milan), Via Manzoni, 56, 20089, Rozzano (Milan), Italy.
Foschino MP; MAR4 Univ., D'Avanzo Hospital, Viale degli Aviatori, 1, 71122, Foggia, Italy.
Prediletto R; Pneumology, Institute of Clinical Physiology, National Research Council of Italy and Toscana G. Monasterio Foundation, Via Giuseppe Moruzzi, 1, 56124, Pisa, Italy.
Simoni L; Medineos Observational Research, Viale Virgilio 54/U, 41123, Modena, Italy.
Ori A; Medineos Observational Research, Viale Virgilio 54/U, 41123, Modena, Italy.
Giovannetti C; Laboratori Guidotti, Via Livornese, 897, 56122, Pisa, Italy.
Barsanti S; Laboratori Guidotti, Via Livornese, 897, 56122, Pisa, Italy.
Scichilone N; DIBIMIS, University of Palermo, Piazza delle Cliniche, 2, 90127, Palermo, Italy.
Źródło:
Advances in therapy [Adv Ther] 2022 Dec; Vol. 39 (12), pp. 5582-5589. Date of Electronic Publication: 2022 Oct 11.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: New York : Springer Healthcare Communications, 2008- : Health Communications Inc.
Original Publication: Metuchen, N.J. : Health Communications Inc., c1984-
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*/therapeutic use
Pulmonary Disease, Chronic Obstructive*
Humans ; Circadian Rhythm ; Muscarinic Antagonists/therapeutic use ; Severity of Illness Index ; Phenotype ; Administration, Inhalation ; Bronchodilator Agents/therapeutic use ; Adrenal Cortex Hormones/therapeutic use ; Drug Therapy, Combination
References:
Hopkinson NS, Molyneux A, Pink J, et al. Guideline Committee (GC) Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance. BMJ. 2019;366: l4486. https://doi.org/10.1136/bmj.l4486 . (PMID: 10.1136/bmj.l448631358491)
Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625–37. https://doi.org/10.1183/13993003.01170-2015 . (PMID: 10.1183/13993003.01170-2015267970354733567)
Ninane V, Corhay J-L, Germonpré P, et al. An Lehouck Inhaled treatment of COPD: a Delphi consensus statement. Int J Chron Obstruct Pulmon Dis. 2017;12:793–801. https://doi.org/10.2147/COPD.S125564.eCollection2017 . (PMID: 10.2147/COPD.S125564.eCollection2017282931065345984)
Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol Actions. 2017;53(6):324–335. doi: https://doi.org/10.1016/j.arbres.2017.03.018 . Epub 2017 May 3.
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://goldcopd.org ; 2014.
Canonica GW, Blasi F, Scichilone N, et al. Characterization of circadian COPD symptoms by phenotype: methodology of the STORICO observational study. Eur J Intern Med. 2017;43:62–8. https://doi.org/10.1016/j.ejim.2017.05.021 . (PMID: 10.1016/j.ejim.2017.05.02128576398)
Miravitlles M, Worth H, Soler Catalauña JJ, et al. Observational study to characterize 24-hour COPD symptoms and their relationship with patient-reported outcomes; results from the ASSESS study. Respir Res. 2014;15:122. https://doi.org/10.1186/s12931-014-0122-1 . (PMID: 10.1186/s12931-014-0122-1253313834220061)
Pokrzywinski RF, Meads DM, McKenna SP, et al. Development and psychometric assessment of the COPD and asthma sleep impact scale (CASIS). Health Qual Life Outcomes. 2009;7:98. (PMID: 10.1186/1477-7525-7-98199688812794842)
Jones PW, Harding G, Berry P, et al. Development and first 470 validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–54. https://doi.org/10.1183/09031936.00102509 . (PMID: 10.1183/09031936.0010250919720809)
Bender R. Lange S Multiple test procedures other than Bonferroni’s deserve wider use BMJ. 1999;318(7183):600–1. https://doi.org/10.1136/bmj.318.7183.600a . (PMID: 10.1136/bmj.318.7183.600a10037651)
Lange P, Marott JL, Vestbo J, et al. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43(6):1590–8. (PMID: 10.1183/09031936.0019671324488571)
Omachi TA, Blanc PD, Claman DM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13(5):476–83. https://doi.org/10.1016/j.sleep.2011.12.007 (Epub 2012 Mar 18). (PMID: 10.1016/j.sleep.2011.12.007224296513336048)
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://goldcopd.org ; 2020.
Vogel-Claussen J, Schönfeld C-O, Kaireit TF et al. Effect of Indacaterol/glycopyrronium on Pulmonary Perfusion and ventilation in Hyperinflated Patients wirh Chronic Obstructive Pulmonary Disease (CLAIM). A Double-Blind, Randomized, Crossover Trial. Am J Respir Crit Care Med. 2019;199(9):1086–1096.
Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368–78. (PMID: 10.1016/S2213-2600(18)30054-729477448)
Contributed Indexing:
Keywords: COPD; Circadian rhythm; Clinical phenotype; Observational; Prescribed therapies; Real-world
Molecular Sequence:
ClinicalTrials.gov NCT03105999
Substance Nomenclature:
0 (Adrenergic beta-2 Receptor Agonists)
0 (Muscarinic Antagonists)
0 (Bronchodilator Agents)
0 (Adrenal Cortex Hormones)
Entry Date(s):
Date Created: 20221011 Date Completed: 20221101 Latest Revision: 20230129
Update Code:
20240105
DOI:
10.1007/s12325-022-02331-x
PMID:
36219388
Czasopismo naukowe
Introduction: While selected clinical and laboratory findings are taken into account to find the best therapeutic strategies for chronic obstructive pulmonary disease (COPD), it is unknown whether the circadian rhythm of respiratory symptoms, a distinctive feature of COPD, affects the prescription pattern of pharmacological therapy. The main aim of this study was to verify whether the circadian rhythm of symptoms correlates with bronchodilating therapy prescribed to COPD patients as per clinical practice. A secondary objective was to assess the relationship between Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage and circadian rhythm of symptoms and health status.
Methods: Five hundred sixty-six COPD patients were enrolled in the Italian multicenter STORICO study. Patients underwent a multidimensional assessment, and correlates of prescribed therapy were assessed through a multivariate multilevel model.
Results: As expected, patients in GOLD D stage were more likely to receive triple inhaled therapy than GOLD A-C patients, but the circadian rhythm of symptoms, assessed by the nighttime, morning, and daytime symptoms of the COPD questionnaire, was unrelated to the prescription pattern. The multivariate model showed that emphysematous (EM) patients had a 50% increased risk compared with patients affected by chronic bronchitis (CB) of being prescribed long-acting β2-agonists (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) instead of triple therapy [relative risk (RR) EM versus CB 1.50, 95% CI 1.11, 2.03]. Symptoms, mainly in the early morning and daytime, were highly prevalent, even in GOLD B stage (76%).
Conclusion: Even if we cannot infer about causality of the symptoms-therapy relationship, based on the structured recording of circadian symptoms clearly shows that symptoms are poorly controlled as the circadian rhythm of symptoms does not correlate with the prescription pattern, and many patients are symptomatic both at daytime and by nighttime. Thus, therapy should be better tailored to the individual needs, with special attention to control nocturnal symptoms.
Trial Registration: ClinicalTrials.gov identifier, NCT03105999.
(© 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies